Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I don't see how frost destroyed shareholder value in pbth
SQNM's test is the most expensive and Ariosa's is the cheapest one.
Doesn't SQNM's MaterniT21 test do this very same thing?
ZTS/PFE quiz
Only thing I can think of is the expected Pfizer's next move - voluntary exchange offer with discount on ZTS share price.
I don't see how Frost destroyed shareholder value in PBTH...
The Teva-Lonza FoB collaboration announced in 2009 (#msg-34930012) appears to be dead, for all practical purposes
Amgen's T-Vec in melanoma
In ph2, they did find that the drug had effect on non-injected lesions, so it implied it did have immune response.
Amgen's T-Vec in melanoma
advantage isn't as extreme as it first appears
Xarelto gets CHMP recommendation for ACS indication:
http://press.healthcare.bayer.com/en/press/news-details-page.php/14953/2013-0172
In this case you'll be delighted to read the PwC 2012 patent litigation study:
http://www.pwc.com/us/en/forensic-services/publications/2012-patent-litigation-study.jhtml
Teva Faces Possible Damages From Selling Generic Protonix
Dolutegravir will take share from Isentress in treatment-experienced patients but as you said, its combo with Epzicom isn't an attractive option to Stribild in first line. Still, Isentress annual sales were about $1.5B last year.
The development of anti-drug antibodies has indeed been associated with worse efficacy but also with hypersensitivity reactions, that in very rare cases could result in anaphylaxis and death. This serious systemic reaction is usually quick i.e hours after injection/infusion. Still, when a patient shows hypersensitivity reaction that is getting worse (like the Swedish patient), it is alerting and treatment should be stopped and anti-drug antibodies test should be perform. It's true that usually these anti-drug antibodies don't kill but keep giving the drug to patients with high titre values is harming anyway because the drug isn't working and their condition worsen (increased disability progression, relapse rate, and MRI lesion formation).
Re: MS Patient Dies From Anti-Drug Antibodies
This attitude would have saved that patient:
Conclusion: An extended ELISA method for measuring anti-natalizumab antibody titres in multiple sclerosis patients on natalizumab therapy may be used for evaluation of antibody persistence. A test at three months may identify patients with high titres, who should discontinue natalizumab therapy, and patients with transient low-titre antibodies, who may continue natalizumab therapy despite development of antibodies.
Do you recall GILD releasing SVR4 rates for either the POSITRON or FISSION studies?
All patients receiving sofosbuvir/RBV became HCV RNA negative on treatment and relapse accounted for all virologic failures.
The only mention of the Procognia-UniTargeting FoB collaboration update (in English), is this words deficient paragraph:
Procognia soared 19.6% Thursday after the biotechnology company said for laboratory results of cells it has developed for growing a generic version of Abbot Labs Humira treatment for rheumatoid arthritis and other ailments.
BTW, I see that GSK has another Lp-PLA2 inhibitor from the same family as darapladib (also from HGS), completed phase II in atherosclerosis and active in AD.
http://www.gsk-clinicalstudyregister.com/protocol_detail.jsp?protocolId=LP2105521&studyId=7D1AFC17-B7CE-4B6E-9179-DFF5E8FA1163&compound=rilapladib
DDXS / GSK / darapladib
The failure of ANTH's drug in ACS isn't a good sign for darapladib probably, although it targets a different class of phospholipase A2 enzyme but same superfamily of pro-inflammatory enzymes associated with atherosclerosis.
Do you know if this plac test Clevelad lab offers is DDXS'?
http://clevelandheartlab.com/Uploads/Public/Documents/Lp-PLA2%20One-pager_v1.pdf
Q: Why would GILD exclude GT2/GT3 and test GT1,4,5,6 in the NEUTRINO study?
Give it time lad, I'll get there one day :)
You’re thinking of OPK
I am, for all intents and purposes, a Botox fan
What programs have Procognia disclosed other than Humira?
FoB collaboration
Procognia collaborates with a Sweedish comp - Uni Targeting Research for the development of biosimilar and biobetter drugs. Today they published (only in Hebrew for now) preclinical results about their version of Humira.
Some AD statistics to worry about
Quiz: What does a urologist do differently to treat a patient with Botox for: a) neurologically-based urinary incontinence; vs. b) idiopathic urinary incontinence?
GT3 patients will also have the option to be treated with Sofosbuvir/PegRiba until a more viable oral combination is developed.
It was on a local report that the board of directors hired Citigroup because they are frustrated and want to sell the company. So we know it's for sale but what about the buyer? rumors from PLX were they want $1B but I think will take less.
HCV rule of thumb: On average, cirrhotic patients will have 10-15% lower SVR (in absolute terms) than non-cirrhotic patients.
Sofosbuvir + ribavirin for 12w doesn't cut it in genotype-3
Perhaps this will result in an off-label use of sofo+dacla combo in GT3 patients.
You are thinking of patients while GILD is thinking of making max profit.
I'm not even sure the 7% difference doesn't show stst-sig non inferiority to SOC and while I agree that the right way would be to separate GT2 and 3 and find a better combo for GT3, I think that in light of SOC, no options, no resistance, the FDA will approve.
The Sofosbuvir/Daclatasvir oral combo demonstrated 100% SVR24 rates in GT2/GT3 patients (Phase 2 / n=14).
I sure hope so :)
If i were a GT3 patient, i'd still rather try the 12-weeks Sofo/Riba oral treatment first, knowing no resistance to sofo jeopardize my future treatment options in case i relapse.
The stock jumps some 24% at TASE now on buyout rumors
Rosetta Green was a spin-off from ROSG but ROSG sold almost all its stake for peanuts. MON is shopping/investing in Israel for the 4th time now (Beeologics, Evogene, abseeds).
Rosetta Green was a spin-off from ROSG but ROSG sold almost all its stake for peanuts. MON is shopping/investing in Israel for the 4th time now (Beeologics, Evogene, abseeds).
The other interesting speculation is whether there is any correlation between PD-L1 expression and outcomes for immune therapies like Dendreon's.